BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 31711994)

  • 21. Repurposing antidepressants for anticancer drug discovery.
    Song Y; Yang X; Yu B
    Drug Discov Today; 2022 Jul; 27(7):1924-1935. PubMed ID: 34728374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of STAT3 signaling in mediating tumor resistance to cancer therapy.
    Tan FH; Putoczki TL; Stylli SS; Luwor RB
    Curr Drug Targets; 2014; 15(14):1341-53. PubMed ID: 25410411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting STAT3 in cancer: how successful are we?
    Yue P; Turkson J
    Expert Opin Investig Drugs; 2009 Jan; 18(1):45-56. PubMed ID: 19053881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug repurposing for breast cancer therapy: Old weapon for new battle.
    Aggarwal S; Verma SS; Aggarwal S; Gupta SC
    Semin Cancer Biol; 2021 Jan; 68():8-20. PubMed ID: 31550502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small-molecule drug repurposing to target DNA damage repair and response pathways.
    Brinkman JA; Liu Y; Kron SJ
    Semin Cancer Biol; 2021 Jan; 68():230-241. PubMed ID: 32113999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors.
    Mankan AK; Greten FR
    Expert Opin Investig Drugs; 2011 Sep; 20(9):1263-75. PubMed ID: 21751940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation.
    Dong J; Cheng XD; Zhang WD; Qin JJ
    J Med Chem; 2021 Jul; 64(13):8884-8915. PubMed ID: 34170703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Machine and deep learning approaches for cancer drug repurposing.
    Issa NT; Stathias V; Schürer S; Dakshanamurthy S
    Semin Cancer Biol; 2021 Jan; 68():132-142. PubMed ID: 31904426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An update on investigational therapies that target STAT3 for the treatment of cancer.
    Santoni M; Miccini F; Cimadamore A; Piva F; Massari F; Cheng L; Lopez-Beltran A; Montironi R; Battelli N
    Expert Opin Investig Drugs; 2021 Mar; 30(3):245-251. PubMed ID: 33599169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
    Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
    Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Highlighted STAT3 as a potential drug target for cancer therapy.
    Lee H; Jeong AJ; Ye SK
    BMB Rep; 2019 Jul; 52(7):415-423. PubMed ID: 31186087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling.
    Zhang L; Song Q; Zhang X; Li L; Xu X; Xu X; Li X; Wang Z; Lin Y; Li X; Li M; Su F; Wang X; Qiu P; Guan H; Tang Y; Xu W; Yang J; Zhao C
    Invest New Drugs; 2020 Apr; 38(2):311-320. PubMed ID: 31087223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phyotochemical candidates repurposing for cancer therapy and their molecular mechanisms.
    Jung JH; Hwang J; Kim JH; Sim DY; Im E; Park JE; Park WY; Shim BS; Kim B; Kim SH
    Semin Cancer Biol; 2021 Jan; 68():164-174. PubMed ID: 31883914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. STAT3 and metabolism: how many ways to use a single molecule?
    Demaria M; Camporeale A; Poli V
    Int J Cancer; 2014 Nov; 135(9):1997-2003. PubMed ID: 24500994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancing cancer therapy: The role of drug delivery systems in STAT3 inhibitor efficacy and safety.
    Wang KN; Zhou K; Zhong NN; Cao LM; Li ZZ; Xiao Y; Wang GR; Huo FY; Zhou JJ; Liu B; Bu LL
    Life Sci; 2024 Jun; 346():122635. PubMed ID: 38615745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.
    Yang H; Chen X; Li K; Cheaito H; Yang Q; Wu G; Liu J; Dou QP
    Semin Cancer Biol; 2021 Jan; 68():105-122. PubMed ID: 31883910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scaffold Repurposing of Old Drugs Towards New Cancer Drug Discovery.
    Chen H; Wu J; Gao Y; Chen H; Zhou J
    Curr Top Med Chem; 2016; 16(19):2107-14. PubMed ID: 26881709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small molecule inhibitors of STAT3 for cancer therapy.
    Zhao M; Jiang B; Gao FH
    Curr Med Chem; 2011; 18(26):4012-8. PubMed ID: 21824090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protective role of anticancer drugs in neurodegenerative disorders: A drug repurposing approach.
    Advani D; Gupta R; Tripathi R; Sharma S; Ambasta RK; Kumar P
    Neurochem Int; 2020 Nov; 140():104841. PubMed ID: 32853752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report.
    Haftchenary S; Avadisian M; Gunning PT
    Anticancer Drugs; 2011 Feb; 22(2):115-27. PubMed ID: 21063201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.